# Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

> **NCT06809374** · — · COMPLETED · sponsor: **Kochi University** · enrollment: 100 (actual)

## Conditions studied

- Pancreatic Cancer Resectable

## Interventions

- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT06809374
- **Lead sponsor:** Kochi University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06809374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06809374, "Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06809374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*